[Expression and clinical significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor in renal cell carcinoma].
To explore the expression and clinical significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor (PD-ECGF) in renal cell carcinoma. The expression of PD-ECGF in 76 specimens of renal cell carcinoma from June 2002 to December 2006 was examined by EnVision immunohistochemistry. The correlation of the expression of PD-ECGF with the clinicopathological characteristics and prognosis in renal cell carcinoma patients were analyzed. Among 76 renal cell carcinoma patients, 41 patients had a high-level expression of PD-ECGF while another 35 patients a low-level expression. The expression of PD-ECGF was positively correlated with tumor stage and histological grade. The 5-year overall survival rate was significant lower in the patients with a high-level expression of PD-ECGF (60.98% vs 94.29%, P = 0.000). Univariate analysis showed that the characteristics with the prognostic significance for survival were tumor stage, lymph node metastasis, distant metastasis, histological grade and the expression of PD-ECGF. Multivariate analysis showed that tumor stage, histological grade and the expression of PD-ECGF were independent prognostic factors (OR: 17.971, 9.702, 6.790, 95%CI: 3.010 - 107.290, 1.835 - 51.305, 1.156 - 39.894). The expression of PD-ECGF may play an important role in the development and invasion of renal cell carcinoma. An elevated level of PD-ECGF is probably correlated with the prognosis of renal cell carcinoma.